Mucopolysaccharidosis Type II (MPS II)

Mucopolysaccharidosis Type II (MPS II) is the indication for 2 drugs in DrugBank. It is covered by 3 curated, structured indications.

Also known as: Mucopolysaccharidosis II · Hunter Syndrome · MPS II · Mucopolysaccharidosis II (MPS II) · Hunter Disease
Classified under: Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Mental Disorders
Mutations
Nervous System Diseases
Nutritional and Metabolic Diseases
Pathological Processes
Skin and Subcutaneous Tissue Diseases
Indicated drugs: Idursulfase
Tividenofusp alfa

Resolves to

Vocabularies

MeSHM0025232ICD-10E76.1SNOMED CT190936000MedDRA10056889UMLSC0026705

What you can answer from here — as of October 26, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

56Clinical trialsPhase, status and sponsor resolved per trial

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Mucopolysaccharidosis Type II (MPS II) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.